Epigenomics AG

EQS-News: Epigenomics AG publishes financial results for fiscal year 2023

Retrieved on: 
Wednesday, April 10, 2024
EUR, Supervisory board, AG, Research, Sale, ECX, HGB, Epigenomics AG, Bank statement, News, Investment, Patent, CSO, Commercial code, Lithium

Berlin (Germany), March 14, 2024 – Epigenomics AG (FSE: ECX, the “Company”) today reported financial results (according to HGB) for fiscal year 2023.

Key Points: 
  • Berlin (Germany), March 14, 2024 – Epigenomics AG (FSE: ECX, the “Company”) today reported financial results (according to HGB) for fiscal year 2023.
  • In July 2023, Epigenomics AG entered into an agreement with New Day Diagnostics LLC for the sale of substantially all of its assets, which was approved by the Extraordinary General Meeting in September 2023 and closed in October 2023.
  • Based on the measures taken, Epigenomics AG expects that the available financial resources will be sufficient until 2026.
  • The annual financial statements for the 2023 fiscal year can be found on the Epigenomics website at: https://www.epigenomics.com/news-investors/financial-reports/ .

EQS-News: Epigenomics AG: Jochen Hummel appointed to the Supervisory Board to replace Heikki Lanckriet

Retrieved on: 
Thursday, February 15, 2024
Supervisory board, Investment, Supervision, Epigenomics AG, Epigenomics, AG, News, ECX, Annual, WSB, MBB, Security (finance)

Berlin, February 15, 2024 - Epigenomics AG (Frankfurt General Standard: ECX; the “Company”), a holding company focusing on investments in the field of minimally invasive blood tests for cancer detection, announces that upon application of the Executive Board and the Supervisory Board, the Charlottenburg District Court has appointed Mr. Jochen Hummel as a member of the Company's Supervisory Board effective February 5, 2024.

Key Points: 
  • Berlin, February 15, 2024 - Epigenomics AG (Frankfurt General Standard: ECX; the “Company”), a holding company focusing on investments in the field of minimally invasive blood tests for cancer detection, announces that upon application of the Executive Board and the Supervisory Board, the Charlottenburg District Court has appointed Mr. Jochen Hummel as a member of the Company's Supervisory Board effective February 5, 2024.
  • Mr. Hummel replaces Dr. Heikki Lanckriet, who stepped down from the Board on January 31, 2024.
  • For the time being, Mr. Hummel's appointment will end with the Annual General Meeting of Epigenomics AG, which is scheduled to take place on May 29, 2024.
  • Jochen Hummel has been a partner at WSB Wolf Beckerbauer Hummel & Partner, Steuerberatungsgesellschaft mbB since 2011.

EQS-News: Epigenomics AG: Supervisory Board of Epigenomics AG appoints Hansjörg Plaggemars as member of the Executive Board

Retrieved on: 
Monday, February 5, 2024
Supervisory board, Supervision, CFO, Housing, KPMG, Investment, Epigenomics AG, ECX, News, AG, University, Software

Berlin, January 31, 2024 - Epigenomics AG (Frankfurt General Standard: ECX; the "Company"), a holding company focusing on investments in the field of minimally invasive blood tests for cancer detection, announces that the Supervisory Board has appointed Mr. Hansjörg Plaggemars to the Executive Board effective February 1, 2024.

Key Points: 
  • Berlin, January 31, 2024 - Epigenomics AG (Frankfurt General Standard: ECX; the "Company"), a holding company focusing on investments in the field of minimally invasive blood tests for cancer detection, announces that the Supervisory Board has appointed Mr. Hansjörg Plaggemars to the Executive Board effective February 1, 2024.
  • Hansjörg Plaggemars (53) has more than 20 years of management experience in finance in various European companies.
  • In 2014, Mr. Plaggemars joined Deutsche Balaton AG and founded his own consulting firm, Value Consult, in 2017.
  • Dr. Helge Lubenow, Chairwoman of the Supervisory Board: „We are very pleased that Mr. Plaggemars with his extensive management experience and expertise in finance is joining Epigenomics AG.“
    „I am looking forward to becoming part of the Epigenomics team,“ said Hansjörg Plaggemars.

EQS-News: Epigenomics AG: Resignation of Supervisory Board Member Dr Heikki Lanckriet (PhD)

Retrieved on: 
Tuesday, January 30, 2024
Epigenomics AG, ECX, Epigenomics, News, AG, Supervisory board, Doctor of Philosophy

Berlin, Germany, January 26, 2024 – Dr Heikki Lanckriet (PhD) has informed the competent bodies of Epigenomics AG (Frankfurt General Standard: ECX, the “Company”) that he resigned as a member of the Company's Supervisory Board with effect as of 22 February 2024.

Key Points: 
  • Berlin, Germany, January 26, 2024 – Dr Heikki Lanckriet (PhD) has informed the competent bodies of Epigenomics AG (Frankfurt General Standard: ECX, the “Company”) that he resigned as a member of the Company's Supervisory Board with effect as of 22 February 2024.
  • The Supervisory Board will seek to find a suitable successor as member of the Company's Supervisory Board and arrange for his/her appointment by court order in accordance with the statutory provisions.
  • The chairwoman of the Supervisory Board, Dr Helge Lubenow, thanks Dr Heikki Lanckriet (PhD) for his commitment and dedication to the company and its employees.
  • 26.01.2024 CET/CEST Dissemination of a Corporate News, transmitted by EQS News - a service of EQS Group AG.

EQS-News: Epigenomics AG Announces Closing of Agreement on the Acquisition of Almost All of the Company's Assets and Adjustment of Guidance for 2023

Retrieved on: 
Tuesday, October 17, 2023
News, USD, EBITDA, Supervisory board, AG, Epigenomics AG, RTÉ Executive Board, Patient, Sale, Epigenomics, Security (finance), Bank, Rare-earth element

As a result, almost all of the Company's assets have been transferred to New Day Diagnostics.

Key Points: 
  • As a result, almost all of the Company's assets have been transferred to New Day Diagnostics.
  • As part of the closing, the Company has received as consideration a cash payment of USD 0.5 million and an interest in New Day Diagnostics.
  • Jens Ravens, Executive of Epigenomics AG: “The transfer of almost all assets now completed represents the closing of the sale which was overwhelmingly approved by our Extraordinary General Meeting on September 11, 2023.
  • The adjustment results essentially from the income for the year 2023 from the contract with New Day Diagnostics.

New Day Diagnostics Announces Approval of Purchase Agreement by Epigenomics' AG Extraordinary General Meeting

Retrieved on: 
Thursday, September 14, 2023
Science, Other Science, Biotechnology, Research, Pharmaceutical, Oncology, Health, Genetics, Extraordinary general meeting, Epigenomics AG, Cancer, Sale, Organization, Estate (law), Acquisition, Aktiengesellschaft, Patient, Colorectal cancer, Epigenomics, Medical device, Medical imaging

New Day Diagnostics is pleased to announce that the Extraordinary General Meeting of Epigenomics AG (Frankfurt General Standard: ECX1), a molecular diagnostics company focused on blood testing for the early detection of cancer, has approved the acquisition agreement between the two organizations.

Key Points: 
  • New Day Diagnostics is pleased to announce that the Extraordinary General Meeting of Epigenomics AG (Frankfurt General Standard: ECX1), a molecular diagnostics company focused on blood testing for the early detection of cancer, has approved the acquisition agreement between the two organizations.
  • The agreement's completion will further enhance New Day Diagnostics' ability to improve lives by empowering people with innovative, accessible diagnostics.
  • “New Day Diagnostics is thrilled that the resolutions required for the execution of this Agreement have been successfully passed,” said Eric Mayer, President and CEO of New Day Diagnostics.
  • Additionally, the Extraordinary General Meeting gave the green light to amend the statutory purpose of Epigenomics AG, aligning it with the future purpose of Epigenomics AG and the strategic goals of the acquisition.

EQS-News: Epigenomics AG: Pareto and Warburg publish analyst research reports

Retrieved on: 
Tuesday, September 5, 2023
Warburg, Epigenomics AG, Supervisory board, Research, Sale, EUR, RTÉ Executive Board, Hold, Southwestern Advantage, Pareto, Cryptocurrency, Epigenomics

Berlin (Germany), September 5, 2023 - Epigenomics AG (Frankfurt General Standard: ECX1; the "Company") announces that the research reports recently published by Pareto Securities AS and Warburg Research GmbH issue buy recommendations for Epigenomics AG's share.

Key Points: 
  • Berlin (Germany), September 5, 2023 - Epigenomics AG (Frankfurt General Standard: ECX1; the "Company") announces that the research reports recently published by Pareto Securities AS and Warburg Research GmbH issue buy recommendations for Epigenomics AG's share.
  • Both analysts consider the sale of substantial assets to New Day Diagnostics LLC as a chance to realize the potential and value of Epigenomics' blood-based colorectal cancer test Epi proColon “Next-Gen”.
  • With the shift from "Hold" to "Buy", Warburg even indicates that they consider the sale of significant assets likely to be more advantageous for shareholders than a further independent development.
  • Pareto and Warburg set the price target at EUR 3.15 and EUR 3.30, respectively, subject to approval by Epigenomics AG's shareholders at the Extraordinary General Shareholders' Meeting on September 11, 2023, in Berlin.

EQS-News: Epigenomics AG publishes financial results for the first six months 2023

Retrieved on: 
Thursday, August 10, 2023
Executive, CMS, Fairness, Epigenomics AG, Supervisory board, FSE, USD, Sale, Medicare, EUR, Federal Executive Boards, EBITDA, IDW, ECX, Supervision, R, FDA, German Institute for Economic Research, Raute (company), Security (finance), Pharmaceutical industry, Bank, Audit, Lithium, Epigenomics

Berlin (Germany), August 10, 2023 - Epigenomics AG (FSE: ECX, the "Company") today reported financial results (IFRS, unaudited) for the second quarter and first half of 2023.

Key Points: 
  • Berlin (Germany), August 10, 2023 - Epigenomics AG (FSE: ECX, the "Company") today reported financial results (IFRS, unaudited) for the second quarter and first half of 2023.
  • Ultimately, an agreement was reached with New Day Diagnostics LLC on July 24, 2023, to sell substantially all of Epigenomics' assets.
  • In terms of cash consumption, Epigenomics forecasts a range of EUR 7.0 million to EUR 9.0 million for the current full year 2023.
  • The interim statement for the first half of 2023 (unaudited) can be found on Epigenomics' website at: https://www.epigenomics.com/news-investors/financial-reports/ .

Talis Biomedical Announces Andrew Lukowiak, Ph.D., as President and Chief Scientific Officer (CSO)

Retrieved on: 
Wednesday, August 2, 2023
Employment, University, Hologic, Pharmacogenomics, Pennsylvania State University, Infection, Epigenomics AG, Health equity, Physician, Epigenomics, POC, Talis, Medical device, Science, Genetics, Biology

Dr. Lukowiak has more than 20 years of senior leadership experience in the clinical diagnostics industry at both publicly traded and privately held commercial-stage companies.

Key Points: 
  • Dr. Lukowiak has more than 20 years of senior leadership experience in the clinical diagnostics industry at both publicly traded and privately held commercial-stage companies.
  • As a member of the executive leadership team, he will be responsible for leading the assay development, platform engineering, operations, regulatory and clinical affairs functions for Talis Biomedical.
  • “We are thrilled to welcome Andrew to our leadership team as we continue to develop the Talis One® test menu and plan to initiate clinical studies to support our pursuit of multiple 510(k) clearances,” said Rob Kelley,” chief executive officer at Talis Biomedical.
  • Prior to this, he was the chief executive officer at Millenium Health, a leading national toxicology laboratory specializing in clinical testing to support physicians in their treatment of substance use disorder.

New Day Diagnostics LLC Reinforces Commitment to Early Cancer Intervention with Its intention to Acquire the Assets of Epigenomics AG

Retrieved on: 
Monday, July 24, 2023
Other Health, Research, Pharmaceutical, Oncology, Medical Devices, Infectious Diseases, Genetics, Science, Biotechnology, Alternative Medicine, Other Science, Health, DNA, Intellectual property, CMS, CRC, Merchant, Epigenomics AG, Cancer, Sale, Death, Acquisition, ECX, Patient, Colorectal cancer, OTCQX, Pharmaceutical industry, Medical imaging, Epigenomics

New Day Diagnostics LLC is pleased to announce that it has entered into an asset purchase agreement with Epigenomics AG (Frankfurt Prime Standard: ECX, OTCQX: EPGNY), a molecular diagnostics company focused on blood testing for the early detection of cancer.

Key Points: 
  • New Day Diagnostics LLC is pleased to announce that it has entered into an asset purchase agreement with Epigenomics AG (Frankfurt Prime Standard: ECX, OTCQX: EPGNY), a molecular diagnostics company focused on blood testing for the early detection of cancer.
  • This agreement is the successful result of negotiations previously disclosed by Epigenomics AG in their ad hoc announcement dated June 12, 2023.
  • Today's announcement comes on the heels of New Day Diagnostics’ recent merger with EDP Biotech Corp. and furthers the company’s mission of expanding the availability of cost-effective early-detection products to patients.
  • Under the terms of the agreement, New Day Diagnostics would acquire substantially all of Epigenomics AG’s assets and intellectual property.